We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01527929
Recruitment Status : Completed
First Posted : February 7, 2012
Last Update Posted : December 4, 2013
Information provided by (Responsible Party):

February 2, 2012
February 7, 2012
December 4, 2013
April 2012
November 2013   (Final data collection date for primary outcome measure)
Pharmacokinetic profile of cabazitaxel in study population [ Time Frame: Up to day 10 ]
Same as current
Complete list of historical versions of study NCT01527929 on ClinicalTrials.gov Archive Site
Safety profile of cabazitaxel in study population, as measured by adverse events, clinical, laboratory and ECG parameters [ Time Frame: up to 30 days after the last dosing ]
Same as current
Not Provided
Not Provided
Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment
An Open-label Pharmacokinetic and Safety Study of Cabazitaxel in Patients With Solid Tumors With Moderately and Severely Impaired and With Normal Renal Function

Primary Objective:

- To assess potential impact of moderate and severe renal impairment on the pharmacokinetics of cabazitaxel

Secondary Objective:

- To assess the safety of cabazitaxel in patients with various degrees of renal impairment

The study consists of a screening phase, registration, cabazitaxel administration will start within 5 business days of registration, with 21-day study treatment cycles. Cycle lengths may be extended up to a maximum of 14 additional days in case of unresolved toxicity. Patients continue to receive treatment until they experience, unacceptable toxicities/Adverse Events, disease progression, withdraw their consent, or the investigator decides to discontinue the patient, and the subsequent 30 days follow-up or study cut-off, whichever comes first.

Patients may continue to be treated as long as they are benefiting from study treatment and have not met study withdrawn criteria.

Phase 1
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Neoplasm Malignant
Drug: Cabazitaxel XRP6258
Pharmaceutical form: solution for infusion Route of administration: intravenous
  • Experimental: Cohort A
    Normal renal function - Cabazitaxel administered once every 3 weeks
    Intervention: Drug: Cabazitaxel XRP6258
  • Experimental: Cohort B
    Moderate renal dysfunction - Cabazitaxel administered once every 3 weeks
    Intervention: Drug: Cabazitaxel XRP6258
  • Experimental: Cohort C
    Severe renal dysfunction - Cabazitaxel administered once every 3 weeks
    Intervention: Drug: Cabazitaxel XRP6258
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2013
November 2013   (Final data collection date for primary outcome measure)

Inclusion criteria :

  • Diagnosis of histologically or cytologically proven non-hematologic malignancy. The cancer must be one that is either refractory to standard therapy or for which no standard therapy exists. Cabazitaxel is an adequate treatment option, as judged by investigator.
  • Eastern Cooperative Oncology Group performance status 0 - 2
  • Stable renal function
  • Patients must have adequate liver and marrow function as defined below:

    • Absolute neutrophil count ≥ 1.5x10^9/L
    • Platelets ≥ 100x10^9/L
    • Total bilirubin ≤ 1.0 x the institutions upper limit of normal
    • AST (SGOT)/ALT (SGPT) ≤ 2.5 x the institutions upper limit of normal
    • Alkaline phosphatase ≤ 2.5 x the institutions upper limit of normal
  • Patient may have a Grade 1 or less neurotoxicity at study entry.
  • Life expectancy > 3 months
  • Age ≥ 18 years old
  • If female, subject must use a double contraception method, except if she is sterilized for more than 3 months or postmenopausal.
  • Having given written informed consent prior to any procedure related to the study

Exclusion criteria:

  • Less than 4 weeks have elapsed from prior anticancer therapy (surgery, chemotherapy, radiation therapy, hormonal therapy and immunotherapy). Prior isotope therapy and radiotherapy to ≥ 30% of bone marrow are not allowed.
  • Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, class III or IV congestive heart failure, stroke or transient ischemic attack.
  • Any of the following within 3 months prior to study start: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.
  • Active hepatitis
  • Acute renal failure (new or superimposed to pre-existing chronic renal impairment), nephrotic syndrome.
  • Patients requiring dialysis during the study.
  • History of hypersensitivity to docetaxel or polysorbate 80.
  • Known acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease requiring antiretroviral treatment.
  • Known brain metastases.
  • If female, pregnancy or breast-feeding.
  • Any treatment known to induce CYP isoenzymes (e.g., phenobarbital, phenytoin, carbamazepine, rifampicin, St John's Wort) or to strongly inhibit CYP3A4 activities (e.g., ketoconazole, itraconazole, macrolides, antiprotease agents, etc) is not allowed within 2 weeks before or during the test period of the pharmacokinetic sampling

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Belgium,   Italy,   Netherlands,   Spain,   United Kingdom
2011-001517-14 ( EudraCT Number )
U1111-1121-4512 ( Other Identifier: UTN )
Not Provided
Not Provided
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP